SGS is investing more than $1.7 million to expand its North American biopharmaceutical testing capabilities at its Lincolnshire facility near Chicago, IL. The investment in both expertise and equipment, will extend the biopharmaceutical testing services offered by SGS’s current U.S. and Canadian Life Science facilities. The new services will focus on quality control analysis and stability testing of biopharmaceuticals using state-of-the-art methodologies and instrumentation. Installation of all ...